ENANTA PHARMACEUTICA

ENTA
Delayed Quote. Delayed  - 01/22 04:00:00 pm
47.67USD +1.84%
Business Summary
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Biotechnology & Medical Research - NEC
Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV). It has discovered novel protease inhibitors that are members of the direct-acting-antiviral (DAA) inhibitor classes designed for use against the hepatitis C virus (HCV). These protease inhibitors, developed through its collaboration with AbbVie Inc. (AbbVie), include paritaprevir and glecaprevir (ABT-493). Its product candidates also include EDP-305, which is a farnesoid X receptor (FXR) agonist product candidate for NASH and PBC, and EDP-938, which is a clinical candidate for RSV.

Number of employees : 141 people.
Sales per Business
20192020
USD
(in Million)
%USD
(in Million)
%
Small Molecule Drugs 205.20100% 122.47100%
Sales per region
20192020
USD
(in Million)
%USD
(in Million)
%
United States 205.20100% 122.47100%
Managers
Name Title
Jay R. Luly President, Chief Executive Officer & Director
Bruce Leonard Andrews Carter Non-Executive Chairman
Paul J. Mellett CFO & Senior VP-Finance & Administration
Yat Sun Or CSO, Senior Vice President-Research & Development
Nathalie Adda Chief Medical Officer & Senior Vice President
Terry C. Vance Lead Independent Director
George S. Golumbeski Independent Director
Lesley Russell Independent Director
Kristine Peterson Independent Director
Mark G. Foletta Independent Director
Shareholders
Name Equities %
Farallon Capital Management LLC 1,775,000 8.84%
The Vanguard Group, Inc. 1,688,702 8.41%
Apex Capital Management, Inc. 1,292,751 6.44%
Alan J. Dworsky 1,209,773 6.03%
Renaissance Technologies LLC 1,029,000 5.12%
Eagle Asset Management, Inc. 1,001,572 4.99%
T. Rowe Price Associates, Inc. (Investment Management) 974,429 4.85%
SSgA Funds Management, Inc. 963,518 4.80%
Krensavage Asset Management LLC 825,329 4.11%
BlackRock Fund Advisors 700,412 3.49%
Company contact information
Enanta Pharmaceuticals, Inc.
500 Arsenal Street
Watertown, MA 02472

Phone : +1.617.607.0800
Fax : +1.617.607.0530
Web : http://www.enanta.com
Sector Biotechnology & Medical Research - NEC
1st jan.Capi. (M$)
ENANTA PHARMACEUTICALS, INC.13.23%960
MODERNA, INC.25.41%51 846
LONZA GROUP AG5.34%50 271
CELLTRION, INC.-13.65%38 245
IQVIA HOLDINGS INC.3.58%35 582
SEAGEN INC.4.35%33 059
HANGZHOU TIGERMED CONSULTING CO.,LTD13.79%24 266
INCYTE CORPORATION7.96%21 438
ALNYLAM PHARMACEUTICALS, INC.32.63%20 027
PHARMARON BEIJING CO., LTD.29.82%18 864
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.12.56%13 937
CRISPR THERAPEUTICS AG23.11%13 932
BIO-TECHNE CORPORATION12.29%13 768
QIAGEN N.V.2.80%12 355
PPD, INC.1.99%12 203
ICON PUBLIC LIMITED COMPANY10.90%11 412
IONIS PHARMACEUTICALS, INC.9.21%8 634
PRA HEALTH SCIENCES, INC.5.44%8 484
ACADIA PHARMACEUTICALS INC.-1.18%8 399
SYNEOS HEALTH, INC.11.68%7 907
UNITED THERAPEUTICS CORPORATION10.49%7 453